CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. The grant comes from the ...
As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497. ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £18.00. The company’s shares closed yesterday at p1,497. ...
We have reported here the results of studies of the immunogenicity and reactogenicity of this vaccine in patients at increased risk of severe influenza or developing influenza-related ...
GSK’s ViiV Healthcare has suspended development of a Phase 2-stage HIV antiviral named VH3739937, a GSK spokesperson confirmed to Endpoints News on Tuesday.
GlaxoSmithKline Pharmaceuticals Limited is ... Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta.
Background: This study (NCT00383123) compared the immunogenicity and safety of 2 trivalent inactivated influenza vaccines: Fluarix [GlaxoSmithKline (study vaccine)] and Fluzone [Sanofi Pasteur ...
We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where GSK plc (NYSE:GSK) ranks among the top ten global stocks to buy. With the third quarter of ...
Flu, vaccines are coming. Ahead of 2023, the flu vaccination campaign is set to start across Italy. From Emilia Romagna to Veneto and Lombardy, many regions have decided to begin the immunization ...